Logo image of CRVL

CORVEL CORP (CRVL) Stock Fundamental Analysis

NASDAQ:CRVL - Nasdaq - US2210061097 - Common Stock - Currency: USD

113.67  -0.64 (-0.56%)

After market: 113.67 0 (0%)

Fundamental Rating

5

Overall CRVL gets a fundamental rating of 5 out of 10. We evaluated CRVL against 102 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making CRVL a very profitable company, without any liquidiy or solvency issues. CRVL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

CRVL had positive earnings in the past year.
In the past year CRVL had a positive cash flow from operations.
Each year in the past 5 years CRVL has been profitable.
Each year in the past 5 years CRVL had a positive operating cash flow.
CRVL Yearly Net Income VS EBIT VS OCF VS FCFCRVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

1.2 Ratios

Looking at the Return On Assets, with a value of 16.37%, CRVL belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
The Return On Equity of CRVL (29.32%) is better than 94.12% of its industry peers.
CRVL has a better Return On Invested Capital (27.12%) than 97.06% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CRVL is significantly above the industry average of 9.53%.
Industry RankSector Rank
ROA 16.37%
ROE 29.32%
ROIC 27.12%
ROA(3y)16.54%
ROA(5y)14.38%
ROE(3y)31.63%
ROE(5y)28.18%
ROIC(3y)28.37%
ROIC(5y)24.01%
CRVL Yearly ROA, ROE, ROICCRVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

CRVL's Profit Margin of 10.12% is amongst the best of the industry. CRVL outperforms 95.10% of its industry peers.
CRVL's Profit Margin has improved in the last couple of years.
CRVL has a better Operating Margin (12.64%) than 85.29% of its industry peers.
In the last couple of years the Operating Margin of CRVL has grown nicely.
CRVL's Gross Margin of 22.40% is in line compared to the rest of the industry. CRVL outperforms 47.06% of its industry peers.
In the last couple of years the Gross Margin of CRVL has remained more or less at the same level.
Industry RankSector Rank
OM 12.64%
PM (TTM) 10.12%
GM 22.4%
OM growth 3Y3.75%
OM growth 5Y2.98%
PM growth 3Y4.56%
PM growth 5Y4.11%
GM growth 3Y-1.18%
GM growth 5Y0.6%
CRVL Yearly Profit, Operating, Gross MarginsCRVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

8

2. Health

2.1 Basic Checks

CRVL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CRVL has more shares outstanding
Compared to 5 years ago, CRVL has more shares outstanding
There is no outstanding debt for CRVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVL Yearly Shares OutstandingCRVL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRVL Yearly Total Debt VS Total AssetsCRVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 19.75 indicates that CRVL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.75, CRVL belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
CRVL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.75
ROIC/WACC2.98
WACC9.1%
CRVL Yearly LT Debt VS Equity VS FCFCRVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.77 indicates that CRVL should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.77, CRVL is doing good in the industry, outperforming 64.71% of the companies in the same industry.
CRVL has a Quick Ratio of 1.77. This is a normal value and indicates that CRVL is financially healthy and should not expect problems in meeting its short term obligations.
CRVL has a better Quick ratio (1.77) than 68.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.77
CRVL Yearly Current Assets VS Current LiabilitesCRVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

CRVL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.31%.
The Earnings Per Share has been growing by 12.42% on average over the past years. This is quite good.
CRVL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.64%.
The Revenue has been growing slightly by 5.95% on average over the past years.
EPS 1Y (TTM)-3.31%
EPS 3Y19.94%
EPS 5Y12.42%
EPS Q2Q%-53.54%
Revenue 1Y (TTM)12.64%
Revenue growth 3Y12.9%
Revenue growth 5Y5.95%
Sales Q2Q%12.69%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVL Yearly Revenue VS EstimatesCRVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CRVL is valuated quite expensively with a Price/Earnings ratio of 27.19.
CRVL's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.60. CRVL is around the same levels.
Industry RankSector Rank
PE 27.19
Fwd PE N/A
CRVL Price Earnings VS Forward Price EarningsCRVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRVL is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRVL is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 70.77
EV/EBITDA 41.15
CRVL Per share dataCRVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of CRVL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.19
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRVL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORVEL CORP

NASDAQ:CRVL (5/20/2025, 8:00:00 PM)

After market: 113.67 0 (0%)

113.67

-0.64 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-19 2025-05-19
Earnings (Next)07-28 2025-07-28
Inst Owners54.51%
Inst Owner Change0.23%
Ins Owners7.26%
Ins Owner Change-0.32%
Market Cap5.84B
Analysts0
Price TargetN/A
Short Float %3.27%
Short Ratio6.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 27.19
Fwd PE N/A
P/S 6.7
P/FCF 70.77
P/OCF 48.8
P/B 19.41
P/tB 22.15
EV/EBITDA 41.15
EPS(TTM)4.18
EY3.68%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.61
FCFY1.41%
OCF(TTM)2.33
OCFY2.05%
SpS16.96
BVpS5.86
TBVpS5.13
PEG (NY)N/A
PEG (5Y)2.19
Profitability
Industry RankSector Rank
ROA 16.37%
ROE 29.32%
ROCE 34.19%
ROIC 27.12%
ROICexc 54.9%
ROICexgc 71.73%
OM 12.64%
PM (TTM) 10.12%
GM 22.4%
FCFM 9.47%
ROA(3y)16.54%
ROA(5y)14.38%
ROE(3y)31.63%
ROE(5y)28.18%
ROIC(3y)28.37%
ROIC(5y)24.01%
ROICexc(3y)45.01%
ROICexc(5y)39.49%
ROICexgc(3y)59.7%
ROICexgc(5y)53.05%
ROCE(3y)35.76%
ROCE(5y)30.26%
ROICexcg growth 3Y1.94%
ROICexcg growth 5Y-3.26%
ROICexc growth 3Y6.17%
ROICexc growth 5Y0.54%
OM growth 3Y3.75%
OM growth 5Y2.98%
PM growth 3Y4.56%
PM growth 5Y4.11%
GM growth 3Y-1.18%
GM growth 5Y0.6%
F-Score7
Asset Turnover1.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 129.78%
Cap/Sales 4.26%
Interest Coverage 250
Cash Conversion 86.25%
Profit Quality 93.54%
Current Ratio 1.77
Quick Ratio 1.77
Altman-Z 19.75
F-Score7
WACC9.1%
ROIC/WACC2.98
Cap/Depr(3y)113.61%
Cap/Depr(5y)111.61%
Cap/Sales(3y)3.98%
Cap/Sales(5y)4.11%
Profit Quality(3y)77.48%
Profit Quality(5y)100.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.31%
EPS 3Y19.94%
EPS 5Y12.42%
EPS Q2Q%-53.54%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.64%
Revenue growth 3Y12.9%
Revenue growth 5Y5.95%
Sales Q2Q%12.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.78%
EBIT growth 3Y17.13%
EBIT growth 5Y9.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.9%
FCF growth 3Y-3.19%
FCF growth 5Y2.01%
OCF growth 1Y38.6%
OCF growth 3Y1.69%
OCF growth 5Y4.76%